Evidence map›Paper›PMID 40538656›Full record

ArticleFrontiers in neurology2025

Efficacy of individualized orelabrutinib-based regimens in relapsed or refractory central nervous system lymphoma.

Yuchen Wu, Xuefei Sun, Liwei Lv, Qu Cui, Jun Qian, Ruixian Xing, Xueyan Bai, Yuedan Chen, Qing Liu, Wenyuan Lai and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuchen WuDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xuefei SunDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Liwei LvDepartment of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Qu CuiDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Jun QianDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Ruixian XingDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xueyan BaiDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yuedan ChenDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Qing LiuDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Wenyuan LaiDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Chunji GaoDepartment of Hematology, Chinese PLA General Hospital, Beijing, China.
Shengjun SunNeuroimaging Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Nan JiDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yuanbo LiuDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Relapsed or refractory central nervous system lymphoma (rrCNSL) lacks established preferred treatment and carries an inferior prognosis. Bruton's tyrosine kinase inhibitor (BTKi) showed promising effectiveness. Orelabrutinib is a second-generation BTKi with a high concentration in cerebrospinal fluid. Methods: In this retrospective analysis, the outcomes of 37 relapsed or refractory central nervous system diffuse large B-cell lymphoma patients who received orelabrutinib, high-dose methotrexate, ifosfamide, etoposide, and dexamethasone (Ore-MIED) or orelabrutinib, high-dose methotrexate, temozolomide and dexamethasone (Ore-MTD) were evaluated. Results: Of the 37 patients included, 11 received Ore-MTD, and 26 received the Ore-MIED regimen. The overall response rate in our cohort was 89.2%, with complete remission achieved in 51.4% of patients and partial remission in 37.8% of patients. The median progression-free survival was observed to be 7.0 months. No statistically significant difference was found in the median progression-free survival between patients receiving different treatment regimens (5.0 months for Ore-MTD versus 13.0 months for Ore-MIED; Conclusion: Our study confirms the effectiveness and safety of Ore-MIED/Ore-MTD in rrCNSL patients, even in those with previous exposure to multiple lines of treatment.

Indexed as

Bruton’s tyrosine kinase inhibitorcentral nervous system lymphomamethotrexateorelabrutinibrelapsed or refractory

Identifiers

PMID40538656
PMCPMC12176547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.